MRI Scanners Can Steer Therapeutics to Specific Target Sites
News Aug 20, 2015
Magnetic resonance imaging (MRI) scanners have been used since the 1980s to take detailed images inside the body – helping doctors to make a medical diagnosis and investigate the staging of a disease.
An international team of researchers, led by Dr Munitta Muthana from the University of Sheffield’s Department of Oncology, have now found MRI scanners can non-invasively steer cells, which have been injected with tiny super-paramagnetic iron oxide nanoparticles (SPIOs), to both primary and secondary tumour sites within the body.
This targeted approach is extremely beneficial for patients as it dramatically increases the efficiency of treatment and drug doses could potentially be reduced – helping to alleviate side effects.
Revolutionary cell-based therapies, which exploit modified human cells to treat diseases such as cancer, have advanced greatly over recent years. However, targeted application of cell-based therapy in specific tissues, such as those lying deep in the body where injection is not possible, has remained problematic.
The new research suggests MRI scanners are the key to administering treatments directly to both primary and secondary tumours wherever they are located in the body.
The study shows that cancer mouse models injected with immune cells carrying SPIOs and armed with the cancer killing oncolytic virus (OV) which infects and kills cancer cells, showed an 800 per cent increase in the effects of the therapy.
Dr Munitta Muthana, from the University of Sheffield, said: “Our results suggest that it is possible to use a standard MRI scanner to naturally deliver cell-based therapies to both primary and secondary tumours which would normally be impossible to reach by injection.
“This not only increases the therapeutic efficacy but also decreases the risk of unwanted side effects.
“The beauty of using the MRI scanner to administer the therapy is that you can also use it for its original purpose providing a real-time image-guide to ensure the treatment has gone where it is needed.”
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE